+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis



Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis



American Journal of Gastroenterology 99(3): 523-526



Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC); however, marked variability in the incidence of CCA in PSC is reported. Furthermore, limited information exists on risk factors for the development of CCA in PSC. The aim of this study was to determine the incidence of CCA in patients with PSC and to evaluate baseline risk factors for the later development of CCA. From a previous study of the natural history of PSC, we identified 161 patients with PSC who did not have CCA at study entry. Patients were followed until a diagnosis of CCA was established, liver transplantation was performed, or death occurred. Patients were followed for a median of 11.5 yr (interquartile range 4.0-16.1 yr). Fifty-nine patients (36.6%) died, 50 patients (31.1%) underwent liver transplantation, and 11 patients (6.8%) developed CCA. The rate of CCA developing was approximately 0.6% per year. Compared to the incidence rates of CCA in the general population, the relative risk of CCA in PSC was significantly increased (RR = 1,560; 95%CI = 780, 2,793; p < 0.0001). On univariate analysis, a history of variceal bleeding (p < 0.001), proctocolectomy (p= 0.01), and lack of symptoms (p= 0.02) were significant risk factors for CCA with the Mayo Risk Score being marginally significant (p= 0.051). Multivariate analysis determined only variceal bleeding to be a significant risk factor for CCA (RR 24.2; 95%CI: 3.3-67.1). No association was found between the duration of PSC and the incidence of CCA. In conclusion, approximately 7% of PSC patients later developed CCA over a mean follow-up of 11.5 yr, which is dramatically higher than the rates in the general population. Variceal bleeding is a major risk factor for the later development of CCA.

(PDF emailed within 0-6 h: $19.90)

Accession: 049321139

Download citation: RISBibTeXText

PMID: 15056096

DOI: 10.1111/j.1572-0241.2004.04067.x


Related references

Cholangiocarcinoma in primary sclerosing cholangitis: Risk factors and clinical presentation. Scandinavian Journal of Gastroenterology 37(10): 1205-1211, 2002

Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. Scandinavian Journal of Gastroenterology 52(2): 242-249, 2016

Incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis. Hepatology 26(4 PART 2): 170A, 1997

Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology 25(12): 1831-1837, 2011

Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Digestive Diseases and Sciences 52(11): 3123-3135, 2007

Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen?. Hepatology 31(1): 247-248, 1999

Cholangiocarcinoma in primary sclerosing cholangitis is associated with long-standing inflammatory bowel disease A long-term follow-up of 394 primary sclerosing cholangitis patients. Hepatology 34(4 Pt 2): 355A, 2001

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. European Journal of Gastroenterology and Hepatology 19(6): 487-491, 2007

Mayo risk score is not predictive of cholangiocarcinoma associated with primary sclerosing cholangitis. Gastroenterology 114(4 PART 2): A1316, April 15, 1998

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?. Current Hepatology Reports 16(2): 124-129, 2017

Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. Current Opinion in Gastroenterology 33(2): 78-84, 2017

No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 14(12): 1806-1812, 2016

Biliary dysplasia in primary sclerosing cholangitis as a marker of increased risk of cholangiocarcinoma. Hepatology 28(4 PART 2): 446A, 1998

Lack of Association Between Nkg2D Polymorphisms and Cholangiocarcinoma (Cca) Risk in Primary Sclerosing Cholangitis (Psc) and Non-Psc Patients. Gastroenterology 142(5): S-922, 2012

Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: A population-based study. Scandinavian Journal of Gastroenterology 32(10): 1042-1045, 1997